as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹80.38
Change
-1.69 (-2.06%)
Open
₹82.48
Prev. Close
₹82.07
Day High
₹83.89
Day Low
₹79.8
Volume Analysis
Traded
6,913
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •High debt-to-equity ratio (3.64)
- •Low return on equity (1.39%)
- •Below-average fundamentals quality score (29/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹87.01 | ₹85.45 | ₹82.92 | ₹81.36 | ₹78.83 | ₹77.27 | ₹74.74 |
| Fibonacci | ₹85.45 | ₹83.89 | ₹82.92 | ₹81.36 | ₹79.8 | ₹78.83 | ₹77.27 |
| Camarilla | ₹81.5 | ₹81.13 | ₹80.75 | ₹81.36 | ₹80.01 | ₹79.63 | ₹79.26 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-0.04%
1 Month
-7.69%
3 Months
-14.18%
6 Months
+25.53%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹35.33
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.79%
Net margin 2.14% × asset turnover 0.84x × equity multiplier 4.89x
Company Overview
Sector
Healthcare
Market Cap
₹202 Cr
P/E (TTM)
5.55
ROE
1.39%
Book Value
₹76.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Bilcare Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 29/100. The strongest factor is Cash Flow (74/100), while Financial Strength (0/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (3.64); low return on equity (1.39%).
TopFund Score — Fundamentals Quality
29/100 — WeakData confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Stock is trading at 1.10 times its book value
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 3.33% over past five years.
- −Promoter holding is low: 30.0%
- −Company has a low return on equity of -2.83% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Bilcare Limited the exchange about the Newspaper Publication of Un-Audited (Standalone and Consolidated) Financial Results for quarter and half ended 30 September 2026
Bilcare approved H1 FY27 results and appointed Mohan Bhandari Chairman effective 3 November 2026.
Bilcare Inc US, a wholly owned non-material subsidiary, dissolved effective 9 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 190 | 175 | 200 | 194 | 202 | 198 | 194 | 186 | 178 | 181 | 188 | 226 | 248 |
| Expenses + | 173 | 158 | 208 | 175 | 194 | 187 | 186 | 175 | 175 | 168 | 171 | 189 | 226 |
| Operating Profit | 17 | 17 | -8 | 19 | 8 | 11 | 8 | 11 | 3 | 13 | 17 | 37 | 22 |
| OPM % | 8.79% | 9.86% | -4.13% | 9.76% | 3.79% | 5.38% | 3.96% | 5.94% | 1.92% | 7.18% | 9.02% | 16.39% | 8.98% |
| Other Income + | 1 | 4 | 9 | 4 | -6 | -6 | 21 | 6 | 4 | 3 | 12 | 0 | 4 |
| Interest | 20 | 21 | 23 | 21 | 24 | 19 | 19 | 19 | 19 | 17 | 18 | 18 | 20 |
| Depreciation | 10 | 11 | 13 | 12 | 11 | 12 | 5 | 12 | 5 | 5 | 5 | 4 | 4 |
| Profit before tax | -13 | -10 | -35 | -10 | -33 | -27 | 6 | -13 | -17 | -6 | 7 | 15 | 2 |
| Tax % | -5.36% | 34.06% | -44.48% | 55.01% | -9.55% | -39.92% | -119.27% | -24.69% | -1.38% | 3.33% | -13.44% | -0.88% | 45.96% |
| Net Profit + | -12 | -14 | -20 | -15 | -30 | -16 | 12 | -10 | -16 | -6 | 8 | 15 | 1 |
| EPS in Rs | -3 | -3 | -5 | -3 | -7 | -3 | 7 | -2 | -2 | 0 | 6 | 5 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -25 | -29 | -14 | 7 | 6 | 13 | -3 | -4 | -12 | -8 | -3 | 21 | 39 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,692 | 2,603 | 2,633 | 2,778 | 2,997 | 1,827 | 623 | 845 | 982 | 747 | 788 | 734 | 843 |
| Expenses + | 2,506 | 2,396 | 2,443 | 2,617 | 2,827 | 1,782 | 572 | 784 | 925 | 708 | 742 | 689 | 754 |
| Operating Profit | 186 | 207 | 190 | 161 | 170 | 45 | 51 | 60 | 57 | 39 | 46 | 45 | 89 |
| OPM % | 7.0% | 8.0% | 7.0% | 6.0% | 6.0% | 2.5% | 8.0% | 7.0% | 6.0% | 5.0% | 6.0% | 6.0% | 11.0% |
| Other Income + | 9 | -87 | 107 | 297 | 59 | 254 | 45 | 44 | 237 | 16 | 12 | 26 | 19 |
| Interest | 236 | 151 | 176 | 249 | 283 | 174 | 76 | 69 | 60 | 82 | 83 | 72 | 73 |
| Depreciation | 191 | 164 | 177 | 416 | 378 | 239 | 46 | 39 | 38 | 45 | 18 | 20 | 18 |
| Profit before tax | -232 | -194 | -56 | -207 | -433 | -114 | -25 | -4 | 196 | -72 | -43 | -21 | 18 |
| Tax % | -7.0% | -58.0% | 42.0% | -4.0% | 5.0% | -13.0% | -55.0% | 3.0% | 74.0% | -18.0% | -35.0% | -19.0% | — |
| Net Profit + | -216 | -82 | -80 | -199 | -453 | -99 | -11 | -4 | 50 | -59 | -28 | -17 | 18 |
| EPS in Rs | -92 | -36 | -36 | -85 | -193 | -44 | -9 | -5 | 6 | -14 | 0 | 1 | 13 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | -12 | -3 | 1 | 6 | 8 | -39 | -66 | 36 | 16 | -24 | 5 | -7 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,073 | 689 | 590 | 376 | -93 | 85 | 63 | 52 | 507 | 474 | 191 | 173 | 155 |
| Borrowings + | 2,311 | 2,122 | 2,014 | 2,089 | 2,270 | 707 | 677 | 690 | 639 | 756 | 689 | 620 | 652 |
| Other Liabilities + | 933 | 786 | 830 | 913 | 888 | 297 | 300 | 362 | 424 | 314 | 21 | 26 | 44 |
| Total Liabilities | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,112 | 1,064 | 1,127 | 1,593 | 1,568 | 924 | 843 | 875 |
| Fixed Assets + | 1,926 | 2,432 | 2,403 | 2,180 | 2,005 | 534 | 494 | 465 | 1,045 | 1,038 | 456 | 432 | 406 |
| CWIP | 218 | 161 | 149 | 170 | 79 | 0 | 0 | 1 | 1 | 1 | 4 | 10 | 8 |
| Investments | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 8 | 11 | 14 | 14 |
| Other Assets + | 2,196 | 1,026 | 904 | 1,051 | 1,003 | 577 | 570 | 661 | 545 | 521 | 453 | 387 | 447 |
| Total Assets | 4,340 | 3,620 | 3,457 | 3,402 | 3,087 | 1,112 | 1,064 | 1,127 | 1,593 | 1,568 | 924 | 843 | 875 |
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -315 | 177 | 300 | 98 | 206 | 256 | 72 | 41 | -7 | 62 | 86 | 128 |
| Cash from Investing Activity + | 247 | -358 | -129 | -203 | -104 | 1,309 | 2 | -4 | 36 | -106 | 81 | -5 |
| Cash from Financing Activity + | 119 | 149 | -155 | 91 | -103 | -1,600 | -83 | -55 | -19 | 36 | -171 | -132 |
| Net Cash Flow | 50 | -32 | 16 | -13 | -1 | -35 | -9 | -18 | 10 | -7 | -3 | -10 |
| Free Cash Flow | -74 | -12 | 165 | -115 | 91 | 1,569 | 69 | 37 | 11 | -34 | 142 | 120 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -170 | 85 | 173 | 75 | 148 | 828 | 141 | 78 | -6 | 162 | 192 | 283 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 69.95% | 69.95% | 69.95% | 69.95% | 69.95% | 69.95% | 69.95% | 69.94% | 69.95% | 69.95% | 69.94% | 69.95% |
| Promoters | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% |
| FII | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Bilcare Ltd. (this stock) | 202 | 5.55 | 1.13 | 1.39% |
| Brooks Lab Limited | 203 | 58.7 | 1.08 | 22.0% |
| Nectar Lifesciences Ltd. | 193 | — | 0.34 | -31.3% |
| Take Limited | 192 | 22.0 | 5.6 | 16.5% |
| Balaxi Pharma Ltd | 175 | 51.8 | 0.69 | 0.59% |
| Makers Laboratories Ltd. | 169 | 22.6 | 2.15 | 3.17% |
| Natural Capsules Limited | 144 | — | 0.66 | -9.45% |
Which Mutual Funds Hold Bilcare Ltd.?
Frequently Asked Questions about Bilcare Ltd.
Bilcare Ltd. (BI) closed at ₹80.38 on NSE on 19 November 2026, down 1.69 (2.06%) from the previous close.
Bilcare Ltd. trades on the NSE (National Stock Exchange of India) under the symbol BI.
Bilcare Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 5.55.
Bilcare Ltd. has a dividend yield of 0.0%.
Bilcare Ltd.'s 52-week high is ₹115.0 and its 52-week low is ₹50.0.
Bilcare Ltd. has a market capitalisation of ₹202 crore.
Bilcare Ltd. has a TopFund Quality Score of 29/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Bilcare Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.